VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2019 | Venetoclax plus obinutuzumab in CKT CLL: analysis from the CLL14 trial

Othman Al-Sawaf
EHA 2019
Chronic Lymphocytic Leukemia Leukemia Chlorambucil Obinutuzumab Venetoclax
CLL14

Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, talks about venetoclax plus obinutuzumab in CKT CLL. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Othman Al-Sawaf

3:47
Novel targeted therapies for CLL
Othman Al-Sawaf • 14 Jun 2020
1:59
The role of MRD as a prognostic & predictive biomarker in CLL
Othman Al-Sawaf • 6 Oct 2022
2:00
Venetoclax plus rituximab or obinutuzumab in CLL after alloHCT
Othman Al-Sawaf • 20 Jun 2019
4:30
CLL14 trial: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil
Othman Al-Sawaf • 14 Jun 2020

Related Videos

1:41
Key challenges of using the intestinal microbiome as a biomarker
Melody Smith
1:32
CAR T-cell therapy: the importance of LTFU
Graham Collins
1:44
The future of AML therapy
Andreas Burchert
0:42
Treating pediatric patients with hematological malignancies
Claudia Rössig
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals